RT Journal
A1 Hollestein LM, Koomen ER, Nijsten T
T1 Chemoprevention for keratinocytic (pre)cancers: Balancing the risks and benefits
JF Archives of Dermatology
JO Archives of Dermatology
YR 2012
FD May 1
VO 148
IS 5
SP 638
OP 640
DO 10.1001/archdermatol.2011.2273
UL http://dx.doi.org/10.1001/archdermatol.2011.2273
AB 
Setting: Eight centers in the United States participated and included 240 patients from January 2001 to November 2006, when the Food and Drug Administration requested termination of this trial after the worldwide withdrawal of rofecoxib.